San Francisco Bay Area biotech stories.
Tuesday, August 28, 2012
Medivation to take 2-for-1 split of soaring stock Sept. 21
Medivation CEO David Hung.
Medivation Inc., whose stock has soared more than 500 percent since early November, will take a 2-for-1 split of its common stock, the company said Tuesday
Due to the promise of its late-stage experimental prostate cancer drug enzalutamide
, the San Francisco-based drug developer (NASDAQ: MDVN) has seen its stock rise to a 52-week high of $103.89, from $16.10 per share less than 10 months ago.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)